NVCR

Neutral

[SCHEDULE 13G/A] NovoCure Ltd Amended Passive Investment Disclosure

Soleus Capital Master Fund, L.P. and its affiliated entities have filed an amended Schedule 13G/A, disclosing a 9.1% passive stake in NovoCure Limited...

Stock Titan 1 week ago 0

Neutral

H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $48

H.C. Wainwright has reiterated its Buy rating for Novocure (NVCR.US) but has adjusted its target price downwards to $48. This decision reflects the fi...

Moomoo 2 weeks ago 0